中國同輻(01763.HK):宜昌原子高科取得鍀標記藥物放射性藥品生產、經營許可證
格隆匯1月11日丨中國同輻(01763.HK)發佈公吿,近日,原子高科(430005)控股子公司宜昌原子高科醫藥有限公司(以下簡稱:宜昌原子高科)順利取得湖北省藥品監督管理局頒發的鍀標記藥物放射性藥品生產、經營許可證。
宜昌原子高科的順利取證,為原子高科放藥產業佈局增添了新的力量。原子高科將加快宜昌原子高科後續建設進度,爭取早日投入生產運營。原子高科也將以此為契機,加速醫藥中心建設,以實際行動踐行“高效高科”理念,加快推進各在建項目進度,進一步完善原子高科全國醫藥中心的網絡佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.